{"id":"cellgram-lc","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cellgram-LC consists of bone marrow-derived mesenchymal stem cells (MSCs) that exert immunomodulatory and anti-inflammatory effects through the secretion of bioactive molecules including cytokines and growth factors. These cells are designed to reduce pathological inflammation, promote angiogenesis, and support tissue regeneration in damaged tissues. The therapy leverages the inherent capacity of MSCs to migrate to sites of injury and modulate both innate and adaptive immune responses.","oneSentence":"Cellgram-LC is an allogeneic mesenchymal stem cell therapy that modulates immune responses and promotes tissue repair through paracrine signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:18.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease (GVHD)"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT04689152","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis","status":"RECRUITING","sponsor":"Pharmicell Co., Ltd.","startDate":"2021-03-02","conditions":"Alcoholic Cirrhosis","enrollment":200},{"nctId":"NCT05093881","phase":"NA","title":"Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study","status":"RECRUITING","sponsor":"Pharmicell Co., Ltd.","startDate":"2021-08-24","conditions":"Alcoholic Cirrhosis","enrollment":100},{"nctId":"NCT03838250","phase":"PHASE1","title":"Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC","status":"UNKNOWN","sponsor":"Pharmicell Co., Ltd.","startDate":"2019-06-20","conditions":"Alcoholic Liver Cirrhosis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologous bone marrow-derived mesenchymal stem cell"],"phase":"phase_3","status":"active","brandName":"Cellgram-LC","genericName":"Cellgram-LC","companyName":"Pharmicell Co., Ltd.","companyId":"pharmicell-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cellgram-LC is an allogeneic mesenchymal stem cell therapy that modulates immune responses and promotes tissue repair through paracrine signaling. Used for Graft-versus-host disease (GVHD), Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}